Blood Coagulation Factor Viii, Ahf Patents (Class 530/383)
-
Patent number: 8828676Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.Type: GrantFiled: October 26, 2011Date of Patent: September 9, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
-
Publication number: 20140249086Abstract: The present invention relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing of the Factor VIII molecule. The invention further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.Type: ApplicationFiled: October 18, 2012Publication date: September 4, 2014Applicant: CSL LimitedInventors: Carsten Horn, Sabine Zollner, Hubert Metzner, Stefan Schulte
-
Patent number: 8816054Abstract: Factor VIII variants and methods of use thereof are disclosed.Type: GrantFiled: April 2, 2012Date of Patent: August 26, 2014Assignee: The Children's Hospital of PhiladelphiaInventors: Valder Arruda, Rodney M. Camire, Nicholas Iacobelli
-
Patent number: 8809501Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: GrantFiled: June 4, 2012Date of Patent: August 19, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20140227766Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.Type: ApplicationFiled: June 1, 2012Publication date: August 14, 2014Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventor: Peter Stanley Gagnon
-
Publication number: 20140221611Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.Type: ApplicationFiled: August 14, 2013Publication date: August 7, 2014Applicant: DYAX CORP.Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
-
Publication number: 20140221618Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: ApplicationFiled: April 15, 2014Publication date: August 7, 2014Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Publication number: 20140206844Abstract: Described is a method for isolating multiple blood products from a single starting material. Isolation of multiple blood products from a single starting material maximizes the efficiency of blood product isolation. In the present invention, one or more blood products are isolated from a blood product material previously depleted of inter-alpha inhibitor protein (I?Ip). This method provides new paths for increasing the efficiency of isolating blood components and providing pharmaceutically acceptable forms of those components.Type: ApplicationFiled: January 16, 2014Publication date: July 24, 2014Applicant: ProThera BiologicsInventor: Yow-Pin LIM
-
Publication number: 20140193880Abstract: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.Type: ApplicationFiled: January 17, 2014Publication date: July 10, 2014Applicant: Asklepios Biopharmaceutical, Inc.Inventor: RICHARD J. SAMULSKI
-
Patent number: 8765665Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.Type: GrantFiled: February 6, 2013Date of Patent: July 1, 2014Assignees: Baxter International Inc., University of ConnecticutInventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
-
Patent number: 8759293Abstract: The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.Type: GrantFiled: November 12, 2010Date of Patent: June 24, 2014Assignee: Grifols Therapeutics Inc.Inventor: Thomas Barnett
-
Publication number: 20140170172Abstract: A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Applicant: PIN Pharma, Inc.Inventor: David I. Cohen
-
Publication number: 20140162956Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.Type: ApplicationFiled: July 8, 2011Publication date: June 12, 2014Inventors: Caroline Ekblad, Lars Abrahmsen
-
Publication number: 20140141488Abstract: Sequence of 55 New Found Proteins—2 new proteins in Cryoprecipitate—8 new proteins in Fraction III—8 new proteins in Prothrombin Complex Concentrate—2 new found proteins in AFCC (Fraction 33)—3 new proteins in Fraction IV and 4 new found proteins in AFOD (Fraction 42)—2 in HemoRAAS®, 3 in FibroRAAS®, 5 in GammaRAAS®, 3 in AFCC®, 1 in Fraction 3-2, 2 in Fraction 3, 4 in FibingluRAAS® (Thrombin), 3 in AFOD®, 1 in AlbuRAAS®, 1 in FibingluRAAS® (High concentrate Fibrinogen), 1 in AFCC® (From fraction IV), 2 in Transferrin from Human Plasma and their name KH1 through KH55, and 16 existing proteins in which good KH healthy cells exists and their application.Type: ApplicationFiled: January 31, 2013Publication date: May 22, 2014Inventor: Kieu Hoang
-
Publication number: 20140121351Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: ApplicationFiled: December 20, 2013Publication date: May 1, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: Stefan Haider, Andreas Ivens, Hanspeter Rottensteiner, Juregen Siekmann, Peter Turecek
-
Publication number: 20140107320Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: Stefan Haider, Hanspeter Rottensteiner, Juergen Siekmann, Peter Turecek
-
Patent number: 8686225Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.Type: GrantFiled: April 17, 2012Date of Patent: April 1, 2014Assignee: Ventria Bioscience Inc.Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
-
Publication number: 20140072561Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.Type: ApplicationFiled: September 17, 2013Publication date: March 13, 2014Applicant: CSL BEHRING GMBHInventors: Thomas Weimer, Stefan Schulte, Hubert Metzner, Ulrich Kronthaler, Holger Lind, Wiegand Lang
-
Publication number: 20140058790Abstract: Methods and compositions described herein relate to processes for the production of deuterated peptides, and the deuterated peptides produced accordingly. Deuterated peptides produced according to methods and compositions described herein may be produced more efficiently than such peptides produced according to prior art processes. The production process of according to methods and compositions described herein may lead to advantages in yield, purity, and/or price for deuterated peptides. Methods of marketing deuterated peptides are also disclosed.Type: ApplicationFiled: November 30, 2011Publication date: February 27, 2014Applicant: AmideBio LLCInventors: Michael H.B. Stowell, Mikhail Plam
-
Publication number: 20140057848Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modified Factor VIII molecules having decreased cellular uptake.Type: ApplicationFiled: September 14, 2011Publication date: February 27, 2014Applicant: NOVO NORDISK A/SInventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
-
Publication number: 20140050693Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.Type: ApplicationFiled: August 9, 2013Publication date: February 20, 2014Applicant: TECHNISCHE UNIVERSITAT MUNCHENInventors: Ame Skerra, Ina Theobald, Martin Schlapschy
-
Publication number: 20140051832Abstract: The object of the present invention is to provide methods for the production of recombinant human Factor VIII, employing specific endoproteases, thus assuring full proteolytic processing of said factor even during its biosynthesis, consequently avoiding additional purification steps. Other objects of the present invention are the recombinant human Factor VIII as obtained by said methods, pharmaceutical compositions, related uses and therapeutic methods.Type: ApplicationFiled: March 11, 2011Publication date: February 20, 2014Applicant: UNIVERSIDADE DE SÃO PAULO - USPInventors: Marcos A. A. Demasi, Mari Cleide Sogayar, Christian Colin
-
Patent number: 8642737Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: GrantFiled: July 29, 2011Date of Patent: February 4, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Andreas Ivens, Peter Turecek, Oliver Zoechling
-
Patent number: 8637640Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.Type: GrantFiled: July 26, 2010Date of Patent: January 28, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20140024808Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: ApplicationFiled: February 1, 2013Publication date: January 23, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA
-
Publication number: 20140018297Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.Type: ApplicationFiled: June 12, 2013Publication date: January 16, 2014Inventors: Gert Bolt, Ditte Marie Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
-
Patent number: 8618259Abstract: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.Type: GrantFiled: March 27, 2012Date of Patent: December 31, 2013Assignee: Nektar TherapeuticsInventors: Mary J. Bossard, Michael D. Bentley, Ping Zhang
-
Publication number: 20130345402Abstract: The present invention relates to a process and apparatus for purifying a molecule of interest from a heterogeneous clarified fluid mixture. The apparatus of the invention generally comprises a continuous perfusion fermentation system, a continuous particle removal system integrated with the perfusion fermentation system; and a continuous purification system integrated with the particle removal system, which is maintained under sterile conditions. The process comprises filtering a heterogeneous clarified fluid mixture by continuous ultrafiltration at a specific flow rate below the transition point of the molecule of interest in the pressure-dependent region of the flux versus TMP curve, wherein the specific flow rate is maintained substantially constant throughout the continuous ultrafiltration.Type: ApplicationFiled: March 12, 2013Publication date: December 26, 2013Applicant: Bayer Healthcare LLCInventor: Bayer Healthcare LLC
-
Publication number: 20130345403Abstract: The present invention relates to methods for stabilizing FVIII in aqueous solutions comprising a relatively high concentration of FVIII. The invention furthermore relates to such aqueous solutions as well as use thereof.Type: ApplicationFiled: November 30, 2011Publication date: December 26, 2013Applicant: NOVO NORDISK A/SInventors: Christian Rischel, Christina Jespersgaard, Are Bogsnes, Janus Krarup
-
Patent number: 8598319Abstract: The invention is related to a process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing freeze-dried concentrates of said proteins comprising the steps of: chromatographic purification comprising the steps of loading an anion exchanger of weak base type with the said solubilized fraction, previously equilibrated with a buffer of a predetermined ionic strength of an alkaline pH, which allows to retain the biological glue, elution of the biological glue by increasing the ionic strength of the said buffer, and separation of FXIII from fibrinogen by addition to at least one part of the biological glue eluate of at least one chemical agent precipitating the FXIII, and recovery of the resulting purified fibrinogen containing supernatant solution, and diafiltration of the fibrinogen, biological glue and resolubilized FXIII solutions, followed by a freeze-drying of said solutions.Type: GrantFiled: June 28, 2006Date of Patent: December 3, 2013Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Nogré Michel, Porte Pierre, Tellier Michel
-
Publication number: 20130296244Abstract: The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor VIII having increased specific activity in comparison to known factor VIII products.Type: ApplicationFiled: November 4, 2011Publication date: November 7, 2013Applicants: Baxter Heathcare SA, Baxter International Inc.Inventors: Chee K. Lai, Roddy Kevin Stafford
-
Patent number: 8575102Abstract: The present invention provides conjugates encompassed by the following structure, wherein: D is a residue of an active agent bearing at least one amino group; and PEG-m is a methoxy end-capped poly(ethylene glycol), and further wherein the active agent is a coagulation factor having a molecular weight of greater than 100 kDa. Methods of making conjugates, and methods for administering conjugates, are also provided.Type: GrantFiled: July 31, 2009Date of Patent: November 5, 2013Assignee: Nektar TherapeuticsInventors: Sean M. Culbertson, Samuel P. McManus, Mary J. Bossard
-
Publication number: 20130288333Abstract: Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.Type: ApplicationFiled: March 12, 2013Publication date: October 31, 2013Inventors: Young Min KIM, Dae Jin KIM, Sung Min BAE, Chang Ki LIM, Se Chang KWON, Gwan Sun LEE
-
Publication number: 20130281671Abstract: The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.Type: ApplicationFiled: July 11, 2011Publication date: October 24, 2013Applicant: Biogen Idec Hemophilia Inc.Inventors: Robert T. Peters, Susan C. Low
-
Publication number: 20130274445Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.Type: ApplicationFiled: January 24, 2013Publication date: October 17, 2013Inventors: Clark Q Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
-
Publication number: 20130267468Abstract: The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose.Type: ApplicationFiled: June 14, 2013Publication date: October 10, 2013Inventors: Myung-Sam CHO, Sham-Yuen Chan
-
Publication number: 20130244283Abstract: The present invention relates to a process for the production of a haemostasis protein by continuous perfusion culturing of a cell culture in suspension, said cell culture expressing said haemostasis protein into said culture suspension, wherein the cell culture flows across a filter module, which filter module leads to a harvest port, the filter module having a mesh size of from 0.1 to 2.9 ?m allowing passage across of the haemostasis protein and wherein the flow across the filter module is an alternating tangential flow. The invention also relates to a protein produced by the process of the invention.Type: ApplicationFiled: October 5, 2011Publication date: September 19, 2013Applicant: NOVO NORDISK HEALTH CARE AGInventor: Jarno Robin
-
Patent number: 8519102Abstract: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.Type: GrantFiled: March 27, 2012Date of Patent: August 27, 2013Assignee: Nektar TherapeuticsInventors: Mary J. Bossard, Michael D. Bentley, Ping Zhang
-
Publication number: 20130202596Abstract: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.Type: ApplicationFiled: July 11, 2011Publication date: August 8, 2013Applicant: BIOGEN IDEC HEMOPHILIA INC.Inventors: Joe Salas, Robert Peters
-
Patent number: 8501694Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: GrantFiled: January 23, 2012Date of Patent: August 6, 2013Assignees: Emory University, Baxter International Inc., Baxter Healthcare SAInventors: John S. Lollar, Garrett E. Bergman
-
Publication number: 20130195799Abstract: The synergistic biomolecule-polymer conjugates are the long-acting, in vivo controlled continuous-release and hybrid synergy systems of biomolecules that provide increased biological activities and enhanced pharmacological properties for achieving greater therapeutic efficacies.Type: ApplicationFiled: August 19, 2011Publication date: August 1, 2013Applicant: PEG BIOSCIENCES, INC.Inventor: Chyi Lee
-
Publication number: 20130190242Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.Type: ApplicationFiled: December 21, 2012Publication date: July 25, 2013Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
-
Publication number: 20130171095Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.Type: ApplicationFiled: October 10, 2012Publication date: July 4, 2013Applicant: Xencor, Inc.Inventor: Xencor, Inc.
-
Publication number: 20130150302Abstract: The present invention provides a biocompatible polymer conjugated to FVIII via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIII, and pharmaceutical compositions comprising such conjugated forms of FVIII.Type: ApplicationFiled: April 28, 2011Publication date: June 13, 2013Applicant: CANTAB BIOPHARMACEUTICALS PATENTS LIMITEDInventor: William Henry
-
Publication number: 20130143818Abstract: The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose.Type: ApplicationFiled: May 29, 2012Publication date: June 6, 2013Applicant: Bayer HealthCare LLCInventors: Myung-Sam Cho, Sham-Yuen Chan
-
Publication number: 20130144039Abstract: An objective of the invention is to provide an adsorbent allowing purification of a blood coagulation factor or a cell adhesion factor under mild conditions, according to simple procedures, and at a low cost and safely while having a high affinity and a high resistance to deterioration, and a method for purifying the blood coagulation factor or the cell adhesion factor; a solution is to apply a polypeptide having peptide fragments represented by formula (1) as the adsorbent for the blood coagulation factor or the cell adhesion factor, and to purify the blood coagulation factor or the cell adhesion factor using the adsorbent: -(Pro-Hyp-Gly)n- Wherein, in formula (1), n is an integer from 2 to 9,000.Type: ApplicationFiled: December 5, 2012Publication date: June 6, 2013Applicant: JNC CORPORATIONInventor: JNC Corporation
-
Patent number: 8454833Abstract: A method is disclosed for filtering a protein in a liquid mixture in a manner that does not substantially damage or otherwise limit the recovery of the protein in the filtration filtrate. The method generally includes passing a liquid mixture containing a protein (e.g., an aqueous vWF mixture) through a filter while applying a counter pressure to the liquid mixture filtrate to accurately reduce and control the pressure differential across the filter. The disclosed method has the advantage that relatively high filtration flow rates can be achieved at relatively low pressure differentials, in contrast to high pressure differentials, which actually reduce the filtration flow rate of protein liquid mixtures. Further, the method can recover substantially all of the protein that is initially present in the liquid mixture.Type: GrantFiled: November 16, 2011Date of Patent: June 4, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Nebojsa Nikolic, Michaela Frey, Wolfgang Grabmayer, Thomas Jancik, Matthias Fried, Klaus Tschetschkowitsch, Kurt Schnecker, Barbara Riegler, Alma Kasapovic
-
Publication number: 20130137638Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: ApplicationFiled: February 5, 2013Publication date: May 30, 2013Applicant: NOVO NORDISK A/SInventor: NOVO NORDISK A/S
-
Patent number: 8445448Abstract: The present invention provides a peptide comprising a core residue sequence derivable from human FVIII which peptide is capable of binding to an MHC class II molecule without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia.Type: GrantFiled: December 3, 2008Date of Patent: May 21, 2013Assignee: Apitope International NVInventor: David Wraith
-
Publication number: 20130123181Abstract: Provided herein are methods and compositions for preventing or reducing an initial immune response to factor VIII in patients suffering from hemophilia A, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor VIII.Type: ApplicationFiled: November 15, 2010Publication date: May 16, 2013Inventors: Kathleen Pratt, Ruth Ettinger, Eddie Arthur James